Gland Pharma Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/wk7c5jg1anox4drkec99sb2e.pdf

Key Takeaways


Cenexi Turnaround & Integration

Srinivas Sadu: "So as a company, I think we should start looking at how Cenexi contributed to Gland, how Gland is contributed to Cenexi rather than independently looking at Cenexi."

US Business & Pricing Dynamics


GLP-1, Peptides & Complex Injectables

Srinivas Sadu: "So our next -- at least next 3-4 years forecast, we are not considering too much of GLP-1 because one is, of course, the patent situation and also the others [like] how the pricing will pan out."

Capex Cycle & Capacity Build-Out


Margins, Mix & Cost Efficiency

Srinivas Sadu: "So if you see there was a price drop of almost 5%-6%, if you compare to the period, we still were able to maintain the margins because our costs have come down."

Pipeline, Partnerships & Long-Term Bets

Srinivas Sadu: "India's pharmacy industry is undergoing one of the most exciting transformations in global health care. Rising R&D investments are fuelling complex molecules, novel therapies and deeper manufacturing capabilities. This is not just growth - it's strategic evolution. India pharma is going from being the pharmacy of the world to becoming a global innovation hub."

Guidance & Commitments

CommitmentSpecificsTimeline
Base business growth floorMinimum 12-13% growth; higher if CMS approval in Europe acceleratesOngoing / FY26+
Long-term organic CAGR15% CAGR over 5 years, organic, excluding inorganic moves5-year horizon
Cenexi EBITDARemain positive on an annualized basis; quarter-to-quarter fluctuation expectedFY26 and beyond
Cenexi strategic returnsInvestments to begin delivering meaningful resultsCalendar 2026 onwards
Brownfield capexApproximately ₹2,000 crore total; next year above ₹400 croreOver next 5 years
Asset turn on new facilityMore than around 3xOn commissioning
New CDMO contract commercialization$25-30 million annual revenue; ₹80 crore dedicated capexFY28 Q3/Q4
Cartridge line readinessNew line delivered next week; validations 4 months; exhibit batches by Q2Q2 FY27
Dalbavancin US approvalGoal date in February; additional data submitted in JanuaryDecision awaited
CMS variation approval in EuropeApproval expected in 6 months~H2 CY26

Key Metrics

MetricQ3 FY26
Consolidated revenue₹1,695.4 crore, up 22% YoY
Base business revenue (ex-Cenexi)₹1,179 crore, up 16% YoY
Cenexi revenue€50 million, up 21% YoY in constant currency; ₹516.4 crore, up 39% YoY
US revenue₹829 crore, up 16% YoY
Europe and other regulated markets revenue₹88.1 crore, up 16% YoY
Rest of World revenue₹187.6 crore, up 12% YoY
India revenue₹74.4 crore, up 32% YoY
Consolidated adjusted EBITDA₹449 crore, up 25% YoY; margin 26%
Base business adjusted EBITDA margin37%
Cenexi EBITDA€1 million (₹14.8 crore), positive vs loss last year
Consolidated adjusted PAT₹279.7 crore, margin 16% vs 15% in Q3 FY25
Overall gross margin66%, broadly in line with previous year, up from 63% in Q2 FY26
Base business gross margin61% vs 63% last year, primarily due to product mix
R&D spend₹65 crore, 5.4% of revenue, up from ₹43.7 crore last year
US volume growth~19% YoY, while price dropped 5%-6%
Cash conversion cycle166 days for 9M FY26, improved from 172 days at end of FY25
Total cash and equivalents₹3,052.5 crore as of Dec 31, 2025, including non-callable deposit of ₹396 crore
External debt (Cenexi level)₹336.3 crore
Capex incurred (9M FY26)₹356.6 crore
FY26 full-year capex guidance (base business)~₹250 crore
Cartridge fill and finish capacity4 crore units currently; expanding to 14 crore units
ANDA filings in the quarter9 filed, 4 approvals received, 9 products launched in the US
RTU bags portfolio20 filed, 16 approved, 13 under development; market opportunity of $685 million
Core development pipeline15 products under active development: 7 505(b)2 filings, 8 ANDAs
New CDMO contract expected annual revenue$25 million to $30 million, starting end of FY28
Organic growth outlook15% CAGR over 5 years